Loading...
Docoh

Statera BioPharma (STAB)

Statera Biopharma is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. Statera has one of the largest platforms of toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. TLRs are a class of protein that plays a key role in the innate immune system. Statera is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. Statera has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to expansion into fibromyalgia and multiple sclerosis.

Company profile

Ticker
STAB
Exchange
CEO
Christopher Zosh
Employees
Incorporated
Location
Fiscal year end
Former names
CLEVELAND BIOLABS INC, Cytocom, Inc.
SEC CIK
Subsidiaries
High Street Acquisition Corporation • Panacela Labs, Inc. • Panacela Labs LLC ...
IRS number
200077155

STAB stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

31 Mar 22
15 Aug 22
31 Dec 22
Quarter (USD) Sep 21 Jun 21 Mar 21 Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 14.22M 14.22M 14.22M 14.22M 14.22M 14.22M
Cash burn (monthly) (no burn) (no burn) 3.21M 554.71K 6.28M 1.17M
Cash used (since last report) n/a n/a 33.87M 5.84M 66.17M 12.36M
Cash remaining n/a n/a -19.65M 8.37M -51.96M 1.86M
Runway (months of cash) n/a n/a -6.1 15.1 -8.3 1.6

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
28 Sep 21 Taunia Markvicka Common Stock, par value $0.005 per share Grant Acquire A No No 0 100,000 0 100,000
9 Sep 21 Barbarick Steve K Common Stock, par value $0.005 per share Grant Acquire A No No 0 60,000 0 60,000
9 Sep 21 Lea Verny Common Stock, par value $0.005 per share Grant Acquire A No No 0 60,000 0 60,000
9 Sep 21 Randy S. Saluck Common Stock, par value $0.005 per share Grant Acquire A No No 0 60,000 0 60,140
5.4% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 29 29
Opened positions 9 29 -69.0%
Closed positions 9 0 NEW
Increased positions 7 0 NEW
Reduced positions 6 0 NEW
13F shares Current Prev Q Change
Total value 761K 5.33M -85.7%
Total shares 2.12M 2.03M +4.6%
Total puts 0 10.1K EXIT
Total calls 0 0
Total put/call ratio Infinity
Largest owners Shares Value Change
Vanguard 389.11K $122K -6.8%
Empery Asset Management 333.02K $105K NEW
Renaissance Technologies 171.92K $54K -16.6%
NTRS Northern Trust 171.11K $54K +335.9%
VIRT Virtu Financial 157.68K $50K +409.2%
Geode Capital Management 130.77K $41K 0.0%
UBS UBS Group AG - Registered Shares 118.67K $37K NEW
Raymond James Financial Services Advisors 112.25K $35K +275.9%
Two Sigma Securities 78.19K $25K NEW
Cambridge Investment Research Advisors 70.25K $22K +17.0%
Largest transactions Shares Bought/sold Change
Potomac Capital Management 0 -381.9K EXIT
Empery Asset Management 333.02K +333.02K NEW
Sabby Management 69.1K -315.49K -82.0%
Eaton Vance Management 0 -154.07K EXIT
NTRS Northern Trust 171.11K +131.86K +335.9%
VIRT Virtu Financial 157.68K +126.72K +409.2%
UBS UBS Group AG - Registered Shares 118.67K +118.67K NEW
Raymond James Financial Services Advisors 112.25K +82.39K +275.9%
Two Sigma Securities 78.19K +78.19K NEW
Two Sigma Investments 58.52K +58.52K NEW

Financial report summary

?
Competition
Curis

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: academic, accrual, adaptive, added, advertising, advice, agency, agonist, Allocate, allocated, allocation, America, anemia, anniversary, arose, ASC, assessment, assist, augment, bacteria, behalf, biopharma, Black, Bridgeway, bundled, California, central, charged, chronic, client, Committee, compound, comprise, concentration, courier, coverage, CRO, Crohn, culmination, Decathlon, decision, deficit, demand, depreciation, deterioration, disagreement, disbursement, disclaimer, discovery, discretionary, distinct, distribution, doubt, doubtful, earlier, efficacy, employment, enable, entity, ERP, eventual, exceed, expenditure, explanatory, explicit, explicitly, explore, expressed, factor, FDIC, fell, final, finalization, finalized, finite, firm, fixed, foreseeable, forma, frequently, Ft, furniture, goodwill, grew, Griffin, guidance, haul, headcount, heavily, hematology, higher, hire, hired, immunology, implicit, implied, important, inability, incremental, innate, insignificant, insurance, insured, internet, Jolla, La, laboratory, leader, leadership, leave, left, light, lived, LJI, LLP, Maryland, maximum, Meaden, mechanism, modulation, Moore, Multiplied, mutual, neutropenia, NIH, Noreen, oral, Organization, pancreatic, paper, parent, passage, patent, payoff, payroll, pediatric, physical, pipeline, pivotal, play, possession, postage, predecessor, preliminary, prepaid, principle, pro, procedure, promised, proportionally, protein, purported, purpose, qualified, Qualitative, quantitatively, question, reached, reaching, recapitalization, receipt, recipient, recovery, relevant, remitted, remote, remove, removed, rendered, repurchase, resource, retroactively, reversal, reverse, role, rose, routine, scope, screening, select, selected, shut, space, STAB, statera, Step, Stone, structure, subscription, successful, symbol, telecommunication, title, toxicity, treatment, trust, Turner, type, typically, uncollectable, unpaid, write, written
Removed: aimed, annually, Article, assignment, assumption, Authority, awarded, BARDA, biodefense, Biomedical, CDMRP, Congressionally, consolidation, critical, CSO, derived, detailed, disrupted, DoD, eliminated, footnote, founding, innovative, intercompany, JWMRP, matching, Norma, Peer, PRMRP, proportional, reduction, Reviewed, shutdown, significantly, subsequently, testing, treasury, variant, variety, Warfighter